What’s Next for Mersana Therapeutics, Inc. (MRSN) After Today’s Big Increase?

March 14, 2018 - By Vivian Park

The stock of Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a huge mover today! The stock increased 13.35% or $1.97 during the last trading session, reaching $16.73. About 237,224 shares traded or 135.87% up from the average. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 8 months positive chart setup for the $380.66 million company. It was reported on Mar, 14 by Barchart.com. We have $17.57 PT which if reached, will make NASDAQ:MRSN worth $19.03 million more.

Analysts await Mersana Therapeutics, Inc. (NASDAQ:MRSN) to report earnings on March, 15. After $-0.35 actual earnings per share reported by Mersana Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 28.57 % negative EPS growth.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Ratings Coverage

Among 3 analysts covering Mersana Therapeutics Inc (NASDAQ:MRSN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mersana Therapeutics Inc had 3 analyst reports since July 24, 2017 according to SRatingsIntel. The stock of Mersana Therapeutics, Inc. (NASDAQ:MRSN) has “Buy” rating given on Monday, July 24 by Leerink Swann. On Monday, July 24 the stock rating was initiated by Cowen & Co with “Buy”. The rating was initiated by J.P. Morgan with “Buy” on Monday, July 24.

More notable recent Mersana Therapeutics, Inc. (NASDAQ:MRSN) news were published by: Globenewswire.com which released: “Mersana Therapeutics to Present at Upcoming Investor Conferences” on December 15, 2017, also Businesswire.com with their article: “Mersana Therapeutics to Present at Wedbush PacGrow Healthcare Conference” published on August 09, 2017, Zacks.com published: “Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season …” on March 07, 2018. More interesting news about Mersana Therapeutics, Inc. (NASDAQ:MRSN) were released by: Bostonglobe.com and their article: “Mersana Therapeutics completes $75 million IPO” published on June 28, 2017 as well as Globenewswire.com‘s news article titled: “Mersana Appoints David A. Spellman as Chief Financial Officer” with publication date: March 12, 2018.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $380.66 million. The firm develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.